An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular Dystrophy

Phase 2

Completed

• Conditions: Muscular Dystrophy, Duchenne

• Registration Number: NCT00033189
• Lead Sponsor: Cooperative International Neuromuscular Research Group

Brief Summary

This study will help to determine the safety and efficacy of the nutritional supplement Coenzyme Q10 when added to steroids as a treatment for Duchenne muscular dystrophy (DMD). Boys with DMD who are enrolled in this study will should be on a stable dose of steroids for at least six months, and will remain on their usual dose throughout the study. They will complete two screening visits within a one-week period, and if enrolled will then have their strength tested monthly for three months before beginning therapy with Coenzyme Q10. Once Coenzyme Q10 therapy is started, participants will have their strength tested monthly for six months. Following the six month treatment period, participants will be given the option to remain on Coenzyme Q10 until the study is completed.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-09
• Study First Submitted: 2002-04-08
• Study First Submitted QC: 2002-04-08
• Study First Posted: 2002-04-09
• Study Completion: 2005-01
• Status Verified: 2010-11
• Last Update Submitted: 2010-11-15
• Last Update Posted: 2010-11-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (2)

Washington University-St. Louis; 🇺🇸 St. Louis, Missouri, United States

Children's National Medical Center; 🇺🇸 Washington, District of Columbia, United States